Genetics of cannabis use in opioid use disorder: A genome-wide association and polygenic risk score study
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0289059 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Alannah Hillmer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada. Hauptthemen laut MEDLINE: Cannabis, Opioid-Related Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, CHIR.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Background
Individuals with an Opioid Use Disorder (OUD) have increased rates of cannabis use in comparison to the general population. Research on the short- and long-term impacts of cannabis use in OUD patients has been inconclusive. A genetic component may contribute to cannabis cravings.
Aims
Identify genetic variants associated with cannabis use through Genome-wide Association Study (GWAS) methods and investigate a Polygenic Risk Score (PRS). In addition, we aim to identify any sex differences in effect size for genetic variants reaching or nearing genome-wide significance in the GWAS.
Methods
The study outcomes of interest were: regular cannabis use (yes/no) (n = 2616), heaviness of cannabis use (n = 1293) and cannabis cravings (n = 836). Logistic and linear regressions were preformed, respectively, to test the association between genetic variants and each outcome, regular cannabis use and heaviness of cannabis use. GWAS summary statistics from a recent large meta-GWAS investigating cannabis use disorder were used to conduct PRS’s. Findings are limited to a European ancestry sample.
Results
No genome-wide significant associations were found. Rs1813412 (chromosome 17) for regular cannabis use and rs62378502 (chromosome 5) for heaviness of cannabis use were approaching genome-wide significance. Both these SNPs were nominally significant (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada.
- Department of Medicine, McMaster University, Hamilton, ON, Canada.
- McMaster University, Hamilton, ON, Canada.
- Universidade Federal do Rio Grande do Sol, Porto Alegre, Brazil.
- NOSM University, Sudbury, ON, Canada.
- Department of Health Research Method, Evidence & Impact, Hamilton, ON, Canada.
ORCID-Profile: Alannah Hillmer, Caroul Chawar, Luciano Minuzzi, Zainab Samaan
Förderung
- CIHR
- CHIR
Zitieren
APA
Hillmer, A., Chawar, C., Lamri, A., Hudson, J., Kapczinski, F., Minuzzi, L., Marsh, D. C., Thabane, L., Paterson, A. D., & Samaan, Z. (2023). Genetics of cannabis use in opioid use disorder: A genome-wide association and polygenic risk score study. PLOS ONE. https://doi.org/10.1371/journal.pone.0289059
Vancouver
Hillmer A, Chawar C, Lamri A, Hudson J, Kapczinski F, Minuzzi L, et al. Genetics of cannabis use in opioid use disorder: A genome-wide association and polygenic risk score study. PLOS ONE. 2023. doi:10.1371/journal.pone.0289059
BibTeX
@article{Hillmer2023,
author = {Hillmer, Alannah and Chawar, Caroul and Lamri, Amel and Hudson, Jacqueline and Kapczinski, Flavio and Minuzzi, Luciano and Marsh, David C and Thabane, Lehana and Paterson, Andrew D and Samaan, Zainab},
title = {Genetics of cannabis use in opioid use disorder: A genome-wide association and polygenic risk score study},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0289059}
}
EUVIMED